PathAI Publications

Efruxifermin drives multidimensional histologic improvement in compensated cirrhosis: an AI-based analysis from the SYMMETRY randomized controlled trial

Written by Admin | Nov 5, 2026, 2:00:00 PM

Conference

AASLD

Partner

Akero Therapeutics

View Presentation